Key result
Lower midwall fractional shortening was associated with a higher risk of heart failure or death (HR 0.89; 95% CI 0.84-0.95; P<0.001) and improved risk reclassification beyond LVEF.
Why the study?
MWFS is more reliable than LVEF in concentric LV geometry, leading researchers to hypothesize it might predict HF and death in high-risk asymptomatic individuals beyond other echocardiographic parameters.
Does midwall fractional shortening (MWFS) predict heart failure and death better than LVEF in asymptomatic patients at high risk for HF?
Cohort (n=623)
Yes
Does midwall fractional shortening (MWFS) predict heart failure and death better than LVEF in asymptomatic patients at high risk for HF?
MWFS is a simple echocardiographic parameter that improves risk stratification for heart failure and death in asymptomatic high-risk patients beyond LVEF.
May support MWFS for HF risk reclassification beyond LVEF in high-risk asymptomatic patients; leaves open prospective validation before practice change.
AIMS: Midwall fractional shortening (MWFS) is a measure of left ventricular (LV) systolic function that is more reliable in case of concentric LV geometry compared to LV ejection fraction (LVEF). We hypothesized that MWFS might predict heart failure (HF) and death in a high-risk asymptomatic population, beyond other echocardiographic parameters. METHODS AND RESULTS: Among 4047 subjects aged ≥55/≤80 years followed by 10 general practitioners in northern Italy, the DAVID-Berg study prospectively enrolled 623 asymptomatic outpatients at increased risk for HF. Baseline evaluation included clinical visit, electrocardiogram, N-terminal pro-brain natriuretic peptide (NT-proBNP), and echocardiogram. Mean age of the population was 69 ± 7 years, 56% were men, 88% had hypertension, mean LVEF was 61 ± 9%, and mean MWFS 16.2 ± 3.3. During a median follow-up of 5.7 years, 95 subjects experienced HF/death events. At Cox analysis, lower MWFS was the only echocardiographic parameter, among structural/functional ones, associated with higher risk of HF/death [hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.84-0.95, Padjusted < 0.001]. The risk of HF/death related to clinical data and NT-proBNP (baseline model) was reclassified by echocardiography only when MWFS was included into the model (baseline C-statistics 0.761; adding conventional structural/functional echocardiographic data 0.776, P = 0.09; adding MWFS 0.791, P = 0.007). Compared to subjects with normal LVEF and MWFS, only subjects with combined systolic dysfunction (11% of the population) were at higher risk (P = 0.001 for both abnormal; P > 0.24 for either LVEF or MWFS abnormal). CONCLUSION: DAVID-Berg data suggest to include MWFS assessment in clinical practice, a simple and reliable echocardiographic parameter able to improve risk stratification in subjects at high risk for HF.
No takes yet. Share an insight, caveat, or question.
Burocchi et al. (2019) conducted a cohort in Asymptomatic outpatients at increased risk for heart failure (n=623). Midwall fractional shortening (MWFS) vs. Conventional structural/functional echocardiographic data (LVEF) was evaluated on Heart failure (HF) and death (HR 0.89, 95% CI 0.84-0.95, p=< 0.001). Lower midwall fractional shortening was associated with a higher risk of heart failure or death (HR 0.89; 95% CI 0.84-0.95; P<0.001) and improved risk reclassification beyond LVEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: